Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer

Hwee‐Yong ‐Y Yap, George R. Blumenschein, Charles K. Tashima, Gabriel N. Hortobagyi, Aman U. Buzdar, Charles L. Wiseman

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5‐FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m2 iv and vincristine 1.5 mg/m2 iv at weekly intervals. Of 17 evaluable patients, 4 (23%) achieved a partial remission with a median duration of remission of 6 months and a median survival of 10 months. In another seven of seventeen patients (41%) the disease remained stable. Toxicity was minimal.

Original languageEnglish (US)
Pages (from-to)32-34
Number of pages3
JournalCancer
Volume44
Issue number1
DOIs
StatePublished - Jul 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer'. Together they form a unique fingerprint.

Cite this